NASDAQ · RGEN
Repligen Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for RGEN has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $0.55 | $0.58 | $0.52 | 4 |
| Mar 2027 | $0.59 | $0.63 | $0.54 | 3 |
| Jun 2027 | $0.65 | $0.67 | $0.64 | 3 |
| Sep 2027 | $0.63 | $0.69 | $0.60 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · MarketBeat · Fintel- RTTNews · Oct 30, 6:35 AM EDTRepligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity(RTTNews) – Repligen Corp. (RGEN), a bioprocessing company, on Friday announced agreements to issue $1 billion in 0.25% convertible senior notes due 2031.
- The Motley Fool · Oct 27, 11:59 AM EDTRepligen (RGEN) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Oct 27, 11:05 AM EDTWhat Repligen (RGEN) Said on Its Q3 Earnings CallWhy Medical Products Maker Repligen May Be A Potential Buy Repligen (NASDAQ:RGEN) reported record third-quarter 2026 revenue of $209 million, surpassing its prior quarterly peak set in the second quarter of 2022, as growth in its Proteins, Chromatography and Analytics franchises
- Fintel · Oct 27, 10:12 AM EDTRepligen Corporation Reports Third Quarter 2026 Revenue of $209 millionRepligen Corporation reported its financial results for the third quarter ended September 30, 2026, with reported revenue of $209 million, representing a year-over-year increase of 11% as reported and 12.5% organic. Under GAAP, the company recorded a loss from operations of $29.5
- Zacks · Oct 27, 7:15 AM EDTRepligen (RGEN) Q3 Earnings and Revenues Surpass EstimatesRepligen (RGEN) delivered earnings and revenue surprises of +15.22% and +1.30%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Oct 7, 4:05 AM EDTRepligen Corp Completes Acquisition Of BioLife Solutions(RTTNews) – Repligen Corp. (RGEN), a life sciences company, announced that it has completed the previously announced acquisition of BioLife Solutions, Inc. (BLFS), a developer and supplier of cell processing tools and services for the cell and gene therapy market.
- The Motley Fool · Oct 6, 6:13 PM EDTWhy Freshworks Stock Bumped Higher TodayIt'll replace a healthcare company that's being acquired.
- RTTNews · Sep 29, 8:07 AM EDTBiotech Stocks At 52-Week Highs – KOD +177% On Phase 3 Data; GRAL, IOVA, RGEN(RTTNews) – The following biotech stocks reached a 52-week high on September 28, 2026, driven by key catalysts such as promising results from clinical trials.
- Zacks · Sep 25, 10:19 AM EDTMerck's Remigromig Meets Main Goal in Diabetic Macular Edema StudyMRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
- Zacks · Sep 23, 9:38 AM EDTAMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease StudyAmgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
- Zacks · Sep 22, 11:15 AM EDTAlkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
- Zacks · Sep 22, 11:13 AM EDTJNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania StudyJ&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Repligen Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.